BCMA-Targeted CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorChongqing Precision Biotech Co., Ltd
About this trial
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Eligibility criteria
Qualifiers
Signed written informed consent;
Failed to standard chemotherapy regimens;
Relapse after complete remission, high-risk and / or refractory patients ;
Relapse after hematopoietic stem cell transplantation;
Disqualifiers
Previous history of other malignancy;
Presence of uncontrolled active infection;
Evidence of disorder that need the treatment by glucocorticoids;
Active or chronic GVHD；
Trial design
Treatments tested in this trial
- BCMA CAR-T cells
Treatment groups
80 Participants
are divided into 1 treatment groupLocations
1920th Hospital of Joint Logistics Support Force KunmingYunnan, China
Sponsors and collaborators
Chongqing Precision Biotech Co., Ltd
Lead sponsor
Source ClinicalTrials.gov